Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

  title={Anti-A$\beta$ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy},
  author={Jacopo C. DiFrancesco and M. Longoni and Fabrizio Piazza},
  journal={Frontiers in Neurology},
Amyloid-related imaging abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer’s disease (AD). Early biomarkers of ARIA represent an important challenge to ensure safe and beneficial effects of immunotherapies, given that different promising clinical trials in prodromal and subjects at risk for AD are underway. The recent demonstration that cerebrospinal fluid (CSF) anti-Aβ autoantibodies play a key role in the development of the ARIA-like… 

Figures and Tables from this paper

Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?

The issue of what is an acceptable balance of treatment side effects is debated, i.e., therapeutic-induced ARIA, versus the positive prospects, as implementation of biomarkers for ARIA might increase value and reduce waste in the design of immunotherapy trials of Alzheimer's disease.

Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies

The first in vivo 11C-PK11195 PET evidence for an association between microglial activation and the magnitude and severity of ARIA-E in patients with increased CSF concentration of anti-Aβ autoantibodies and comorbid AD and CAA disease is provided.

Cerebral Amyloid Angiopathy-Related Inflammation Biomarkers: Where are we Now?

  • A. Charidimou
  • Medicine, Biology
    Journal of Alzheimer's disease : JAD
  • 2016
The current state of biomarkers research for CAA-ri and recently suggested diagnostic criteria are put into context.

Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy

A comprehensive review on their toxicities follows in relation to the characterized epitopes of anti-Aβ mAb candidates under development, and a summary of other novel and promising antibody-based immunotherapeutic approaches that deserve more attention for the effective treatment of AD in the future are provided.

Impact of Cerebral Amyloid Angiopathy in Two Transgenic Mouse Models of Cerebral β-Amyloidosis: A Neuropathological Study

The APP23 mouse model is an interesting tool to study the overlap between vascular and parenchymal Aβ deposition and to evaluate future disease-modifying therapy before its translation to the clinic.

Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy

Given the availability of an anti-Aβ therapy, ARIA monitoring will now be implemented in routine clinical practice, and the simple magnetic resonance imaging sequences used in clinical trials are likely sufficient for effective detection of cases.

Immunotherapy Targeting Amyloid-β Peptides in Alzheimer’s Disease

This chapter addresses progress and developments with regard to active and passive immunization against Aβ and summarizes the current state of clinical trials.

Rodent Models of Amyloid-Beta Feature of Alzheimer’s Disease: Development and Potential Treatment Implications

This review focuses on transgenic rodent models used to study amyloid-beta pathology in AD and discusses the advantages and limitations of these models and their potential therapeutic implications for AD.

Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease

It is concluded that interventions based in a “CSF-sink” of A β will probably produce a steady clearance of Aβ in the ISF and therefore it may represent a new therapeutic strategy in AD.

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Key learnings from the field were incorporated into the gantenerumab phase 3 program, including confirmed amyloid positivity as an entry criterion, an enriched clinical trial population to ensure measurable clinical decline, data-driven exposure-response models to inform a safe and efficacious dosing regimen, and the use of several blood-based biomarkers.



Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Aβ autoantibodies.

A case of a patient with biopsy-proven CAA-ri and prodromal AD, confirmed by means of neuropsychological examination after 20 months follow-up, presenting with ARIA and high levels of cerebrospinal fluid anti-Aβ autoantibodies is described.

Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease.

It is reported that ARIA may arise spontaneously during the course of Presenilin 1 (PSEN1)-associated familial AD (FAD), in an APOE4 homozygous patient, and of the potential risk factors for its development.

Amyloid-related imaging abnormalities in AβPP duplication carriers.

The evolution of an AβPP duplication carrier with an APOE 3/3 genotype presenting ARIA-Effusion and then ARia-Hemosiderin deposit, without anti-amyloid therapy, is suggestive of a possible spontaneously resolutive CAA-ri (not neuropathologically proven).

Anti–amyloid β autoantibodies in cerebral amyloid angiopathy–related inflammation: Implications for amyloid‐modifying therapies

The role of anti–amyloid β (Aβ) autoantibodies in the acute and remission phases of cerebral amyloid angiopathy–related inflammation is investigated.

Serum Anti-Amyloid-β Antibodies and Alzheimer's Disease in Elderly Korean Patients

The results showed that the anti-Aβ antibody level in serum could potentially be used to diagnose the presence of AD.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.

This study is the first to show that passive Aβ immunotherapy with bapineuzumab results in decreases in CSF T-t Tau and P-tau, which may indicate downstream effects on the degenerative process.

Life imitates art

Almost 10% of clinical trial subjects receiving the humanized anti-Aβ antibody bapineuzumab1 developed a condition termed vasogenic edema (VE), consisting of reversible T2-hyperintense signal on MRI in the white matter, leptomeninges, and sulci, sometimes associated with clinical symptoms such as headache, changes in mental status, vomiting, and gait disturbance.

Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity

It is suggested that a humoral immune response to Aβ in AD patients may promote neuronal degeneration, a process with important implications for the future of vaccine-based therapies for AD.

Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult

Focal amyloid deposits around the region of ARIA-H suggest that cerebral amyloids angiopathy may be responsible for the occurrence of ARia in this case.